CardioMEMS-Guided CAR T Cell Therapy for Lymphoma in a Patient With Anthracycline-Induced Cardiomyopathy
- PMID: 34396261
- PMCID: PMC8352178
- DOI: 10.1016/j.jaccao.2020.06.005
CardioMEMS-Guided CAR T Cell Therapy for Lymphoma in a Patient With Anthracycline-Induced Cardiomyopathy
Keywords: CAR, chimeric antigen receptor; CRS, cytokine release syndrome; DLBCL, diffuse large B-cell lymphoma; GDMT, guideline-directed medical therapy; HF, heart failure; LVEF, left ventricular ejection fraction; PAd, pulmonary artery diastolic pressure; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; RHC, right heart catherization; TTE, transthoracic echocardiogram; anthracycline; cardiomyopathy; heart failure; immunotherapy; lymphoma.
Figures


References
-
- Brudno J.N., Kochenderfer J.N. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2018;15:31–46. - PubMed
-
- Hayden P.J., Sirait T., Koster L., Snowden J.A., Yakoub-Agha I. An international survey on the management of patients receiving CAR T Cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT. Curr Res Transl Med. 2019;67:79–88. - PubMed
-
- Abraham W.T., Adamson P.B., Bourge R.C. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658–666. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous